Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
NEWRON PHARMACEUT. EO-20
NP5Current price
8.14 EUR
-0.44 EUR (-5.13%)
Last closed
8.33 EUR
Company
–
ISIN
IT0004147952
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
161 962 655 EUR
Yield for 12 month
+50.70 %
1Y
3Y
5Y
10Y
15Y
NP5
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy. Address: Via Antonio Meucci 3, Bresso, MI, Italy, 20091
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
+9 396 334 EUR
Last Year
+6 047 257 EUR
Current Quarter
+3 643 569 EUR
Last Quarter
+5 500 968 EUR
Current Year
+9 396 334 EUR
Last Year
+6 047 257 EUR
Current Quarter
+3 535 671 EUR
Last Quarter
+5 451 859 EUR
Key Figures NP5
1 year
3 years
5 years
10 years
EBITDA
-11 403 852 EUR
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-23.05 %
PEG Ratio
–
Return On Equity TTM
-14642.56 %
Wall Street Target Price
–
Revenue TTM
8 987 529 EUR
Book Value
-1.66 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
9.2 %
Dividend Yield
–
Gross Profit TTM
6 047 257 EUR
Earnings per share
-0.9 EUR
Diluted Eps TTM
-0.9 EUR
Most Recent Quarter
IV 2023
Quarterly Earnings Growth YOY
–
Profit Margin
-179.13 %
Dividend Analytics NP5
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NP5
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation NP5
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
12.5471
Enterprise Value Revenue
21.5064
Price Sales TTM
18.0208
Enterprise Value EBITDA
-15.435
Price Book MRQ
7.6103
Financials NP5
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators NP5
For 52 weeks
4.23 EUR
11.91 EUR
50 Day MA
8.28 EUR
Shares Short Prior Month
–
200 Day MA
8.23 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart